Previous close | 30.14 |
Open | 30.00 |
Bid | 30.43 x 100 |
Ask | 30.47 x 200 |
Day's range | 29.61 - 30.58 |
52-week range | 27.92 - 59.61 |
Volume | |
Avg. volume | 653,826 |
Market cap | 1.448B |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.66 |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 56.14 |
MASON, Ohio, March 26, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
Karl Dahlquist, Chief Legal Officer of AtriCure Inc (NASDAQ:ATRC), has sold 8,231 shares of the company on March 5, 2024, according to a recent SEC filing.